Microalbuminuria Is Associated With All-Cause and AIDS Mortality in Women With HIV Infection

Christina M. Wyatt, MD,* Donald R. Hoover, PhD,† Qiuhu Shi, PhD,‡ Eric Seaberg, PhD,§ Catherine Wei, MA,¶ Phyllis C. Tien, MD,¶# Roksana Karim, MD,**, Jason Lazar, MD,†† Mary A. Young, MD,‡‡ Mardge H. Cohen, MD,§§ Paul E. Klotman, MD,* and Kathryn Anastos, MD†††

Objectives: Prevalence of microalbuminuria is increased in patients with HIV. Microalbuminuria is associated with increased mortality in other populations, including diabetics, for whom microalbuminuria testing is standard of care. We investigated whether microalbuminuria is associated with mortality in HIV-infected women not receiving antiretroviral therapy.

Methods: Urinalysis for proteinuria and semiquantitative testing for microalbuminuria were performed in specimens from 2 consecutive

Received for publication October 9, 2009; accepted November 13, 2009. From the *Department of Medicine, Mount Sinai School of Medicine, New York, NY; †Department of Statistics and Institute for Health, Health Care Policy and Aging Research, Rutgers, The State University of New Jersey, New Brunswick NJ; ¶School of Health Sciences and Practice, New York Medical College, Valhalla, NY; ¶Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore MD; ‡Albert Einstein College of Medicine, Bronx, NY; ‡Department of Medicine, University of California, San Francisco, CA; #Department of Veterans Affairs Medical Center, Medical Service, San Francisco, CA; **Departments of Pediatrics and Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA; ††Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY; †††Department of Medicine, Georgetown University Medical Center, Washington, DC; §§Department of Medicine, Cook County Hospital, Chicago IL; and ¶¶Departments of Medicine and Epidemiology and Population Health, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY. Support for this work was provided by the National Institutes of Health. The WIHS is funded by the National Institute of Allergy and Infectious Diseases (U01-AI-35004, U01-AI-31834, U01-AI-34994, U01-AI-34989, U01-AI-34993, and U01-AI-42590) and the National Institute of Child Health and Human Development (U01-HD-32632). The study is cofunded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is also provided by the National Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131). C.M.W. is supported by the National Institute of Diabetes and Digestive and Kidney Disease (K23-DK-077568). P.C.T. is supported by NIAID (K23-AI-66943). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.

All authors contributed to the design of this analysis, interpretation of data, and critical revision of the article.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions in this article on the journal’s Web site (www.jaids.com).

Correspondence to: Christina Wyatt, MD, Mount Sinai School of Medicine, Box 1243, One Gustave L. Levy Place, New York, NY 10029, (e-mail: christina.wyatt@mssm.edu).

Copyright © 2010 by Lippincott Williams & Wilkins

INTRODUCTION

Chronic kidney disease and overt proteinuria have been associated with adverse outcomes in HIV-infected patients.1,2 Lower levels of urinary albumin excretion, or microalbuminuria, have also been associated with increased mortality in other patient populations, and routine microalbuminuria testing is now considered standard of care in diabetics.3 Several studies have demonstrated an increased prevalence of microalbuminuria in HIV-infected individuals both before4 and after the introduction of highly active antiretroviral therapy (HAART)5-6; however, the prognostic significance of microalbuminuria in HIV-infected patients is not known.

The Women’s Intergency HIV Study (WIHS) has collected information on HIV disease characteristics, comorbidities, and outcomes in a prospective cohort of women enrolled in the pre-HAART era.7 An earlier analysis in WIHS demonstrated an association between overt proteinuria and increased mortality risk.1 We sought to determine whether microalbuminuria testing also provides prognostic information.

METHODS

The WIHS design has been described previously.7 Briefly, WIHS is an ongoing prospective cohort study that visits in 1547 HIV-infected women enrolled in the Women’s Intergency HIV Study in 1994–1995. Time to death was modeled using proportional hazards analysis.

Results: Compared with women without albuminuria, the hazard ratio (HR) for all-cause mortality was increased in women with 1 (HR: 3.4; 95% CI: 2.2 to 5.2) or 2 specimens positive for either proteinuria or microalbuminuria (HR: 3.9; 95% CI: 2.1 to 7.0). The highest risk was observed in women with both specimens positive for proteinuria (HR: 5.8; 95% CI: 3.4 to 9.8). The association between albuminuria and all-cause mortality risk remained significant after adjustment for demographics, HIV disease severity, and related comorbidities. Similar results were obtained for AIDS death.

Conclusions: We identified a graded relationship between albuminuria and the risk of all-cause and AIDS mortality.

Key Words: HIV, microalbuminuria, mortality, proteinuria

(J Acquir Immune Defic Syndr 2010;55:73–77)
enrolled HIV-infected and at-risk seronegative women in 5 metropolitan areas in the United States. Only HIV-infected women enrolled between October 1994 and November 1995 were included in the current analysis. Demographics and social, medical, and detailed HIV disease history were collected by standardized interview. Prior AIDS-defining illness (ADI) was defined based on the 1993 Centers for Disease Control case definition for AIDS, excluding CD4 <200 cells per cubic millimeter. Laboratory data including CD4, HIV-RNA, hepatitis serologies, hemoglobin, serum albumin, and routine urinalysis were collected at enrollment and semiannually. Serum creatinine testing was performed at enrollment and annually. Estimated Glomerular filtration rate (eGFR) was estimated using the 4-variable Modification of Diet in Renal Disease (MDRD) equation. Because currently available GFR estimates have not been validated in HIV-infected populations, we selected the abbreviated MDRD equation because of the established relationship between decreased MDRD eGFR and increased mortality in other patient populations. The WIHS was approved by the institutional review boards of all sites, and participants provided written informed consent. The current analysis was also approved by the institutional review board of the Mount Sinai School of Medicine.

Urine specimens were collected at study entry and every 6 months. To minimize artifact from cystitis, specimens were excluded from this analysis if the corresponding urinalysis demonstrated pyuria (leukocyte esterase 1+ with a positive or missing urine culture, or leukocyte esterase >1+). By WIHS protocol, urine specimens were not collected during menses. Women with 2 eligible urine specimens were included in this analysis. The index visit was defined as the first visit at which an eligible specimen was obtained. Specimens with protein <1+ were tested for microalbuminuria. Semiquantitative microalbuminuria testing was performed in banked urine specimens under standardized conditions using Clinitek Microalbumin Reagent Strips and the Clinitek 50 Analyzer (Siemens Healthcare Diagnostics, Deerfield, IL). This point-of-care dipstick assay has a sensitivity of 86% compared with clinical laboratory testing and was selected because of its applicability to clinical practice. Frozen specimens were thawed completely before testing. Quality assurance testing was performed with standardized controls (Bio-Rad Laboratories, Hercules, CA). Microalbuminuria was defined as an albumin to creatinine ratio >30 mg/g.

The study exposure was hierarchically defined as follows: (1) Women with urinary protein ≥1+ at both the index visit and the next consecutive eligible visit were considered to have “confirmed proteinuria.” (2) Women with microalbuminuria at both visits or with microalbuminuria at one visit and proteinuria at the other were considered to have “confirmed microalbuminuria.” (3) Women with proteinuria or microalbuminuria at only 1 visit were considered to have “unconfirmed albuminuria.” (4) Women without proteinuria or microalbuminuria on either visit were considered to have no albuminuria.

Data on vital status were collected from medical records, providers, and personal contacts of WIHS participants and from the National Death Index. In cases where the death certificate was not available, the cause of death was ascertained from medical records, providers, or personal contacts, in that order. The cause of death was categorized as AIDS, non-AIDS, or indeterminate, as previously described.

Clinical characteristics at the index visit were summarized for each albuminuria group. When data were missing at the index visit, the value was obtained from the most recent prior visit. Continuous and categorical variables were compared using Kruskall-Wallis and chi-square tests, respectively. All P-values are 2-sided. Kaplan-Meier and proportional hazards models evaluated associations of albuminuria with time to death. Proportional hazards models included baseline characteristics that have previously been associated with short-term mortality in WIHS, demographics, prior ADI, hepatitis C coinfection, log transformed HIV-RNA, CD4, hemoglobin, and serum albumin. Diabetes, blood pressure, and eGFR were also considered for inclusion because of their known association with albuminuria. Survival analyses were left-truncated at the second eligible study visit and were censored at October 31, 1997, based on a prior analysis of WIHS demonstrating minimal HAART use and little effect of HAART exposure on the relationship between other covariates and death before this date. In addition, a sensitivity analysis including HAART use as a time-dependent variable in the multivariate models was performed. All analyses were performed using SAS (version 9.1.3; SAS).

RESULTS

Among 2059 HIV-infected women enrolled in WIHS during 1994 to 1995, 1547 (75%) had at least 2 eligible urine specimens available. Women with inadequate specimens were similar to included participants with respect to age and race ethnicity (data not shown). One-third of women included in this analysis reported a history of ADI at or before the index visit, and only 1% reported HAART use at the time of the index visit (Table 1). Fifty-seven women (3.7%) had similar visit, the value was obtained from the most recent prior visit. Continuous and categorical variables were compared using Kruskall-Wallis and chi-square tests, respectively. All P-values are 2-sided. Kaplan-Meier and proportional hazards models evaluated associations of albuminuria with time to death. Proportional hazards models included baseline characteristics that have previously been associated with short-term mortality in WIHS, demographics, prior ADI, hepatitis C coinfection, log transformed HIV-RNA, CD4, hemoglobin, and serum albumin. Diabetes, blood pressure, and eGFR were also considered for inclusion because of their known association with albuminuria. Survival analyses were left-truncated at the second eligible study visit and were censored at October 31, 1997, based on a prior analysis of WIHS demonstrating minimal HAART use and little effect of HAART exposure on the relationship between other covariates and death before this date. In addition, a sensitivity analysis including HAART use as a time-dependent variable in the multivariate models was performed. All analyses were performed using SAS (version 9.1.3; SAS).

RESULTS

Among 2059 HIV-infected women enrolled in WIHS during 1994 to 1995, 1547 (75%) had at least 2 eligible urine specimens available. Women with inadequate specimens were similar to included participants with respect to age and race ethnicity (data not shown). One-third of women included in this analysis reported a history of ADI at or before the index visit, and only 1% reported HAART use at the time of the index visit (Table 1). Fifty-seven women (3.7%) had confirmed proteinuria, 64 (4.1%) had confirmed microalbuminuria, and 165 (10.7%) had unconfirmed albuminuria. Compared with participants with no albuminuria, women with any level of albuminuria had more advanced HIV disease and were more likely to classify their race as black and to have an eGFR below 60 mL-min⁻¹/1.73 m².

During a median follow-up of 2.1 years, there were 135 deaths, including 97 from AIDS. Kaplan–Meier curves demonstrated a graded relationship between the severity of albuminuria and time to all-cause and AIDS death (Fig. 1). Compared with women with no albuminuria, women with unconfirmed albuminuria (HR: 3.4; 95% CI: 2.2 to 5.2) and confirmed microalbuminuria (HR: 3.9; 95% CI: 2.1 to 7.0) had a higher risk of all-cause mortality, whereas women with confirmed proteinuria had the highest risk (HR: 5.8; 95% CI: 3.4 to 9.8). A similar relationship was observed for AIDS death.

After adjustment, the association of albuminuria with all-cause mortality was partially mitigated but remained significant (Table, Supplemental Digital Content 1, http://links.lww.com/QAI/A27). Compared with women with no albuminuria, the adjusted mortality risk was 2-fold higher.
TABLE 1. Characteristics of WIHS Participants at the Index Visit

<table>
<thead>
<tr>
<th></th>
<th>No Albuminuria (n = 1261)</th>
<th>Unconfirmed Albuminuria (n = 165)</th>
<th>Confirmed Microalbuminuria (n = 64)</th>
<th>Confirmed Proteinuria (n = 57)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age, yrs</strong>*</td>
<td>36.5 (7.7)</td>
<td>38.2 (8.0)</td>
<td>40.2 (7.9)</td>
<td>36.2 (8.5)</td>
</tr>
<tr>
<td><strong>Race</strong>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black (including Hispanic)</td>
<td>659 (52.3%)</td>
<td>114 (69.1%)</td>
<td>51 (79.7%)</td>
<td>45 (79.0%)</td>
</tr>
<tr>
<td>White (including Hispanic)</td>
<td>277 (22.0%)</td>
<td>29 (17.6%)</td>
<td>6 (9.4%)</td>
<td>10 (17.5%)</td>
</tr>
<tr>
<td>Other</td>
<td>325 (25.8%)</td>
<td>22 (13.3%)</td>
<td>7 (10.9%)</td>
<td>2 (3.5%)</td>
</tr>
<tr>
<td><strong>CD4 cell count, cells/mm</strong></td>
<td>408.1 (279.0)</td>
<td>350.7 (276.7)</td>
<td>280.8 (282.7)</td>
<td>304.4 (255.2)</td>
</tr>
<tr>
<td><strong>Log</strong>10 HIV-RNA***</td>
<td>4.2 (0.9)</td>
<td>4.4 (0.9)</td>
<td>4.6 (1.1)</td>
<td>4.8 (0.9)</td>
</tr>
<tr>
<td><strong>Prior ADI</strong></td>
<td>400 (31.7%)</td>
<td>62 (37.6%)</td>
<td>28 (43.8%)</td>
<td>28 (49.1%)</td>
</tr>
<tr>
<td>Hepatitis C coinfection**</td>
<td>420/1225 (34.4%)</td>
<td>74/160 (46.3%)</td>
<td>30/63 (47.6%)</td>
<td>20/56 (35.7%)</td>
</tr>
<tr>
<td>Hepatitis B coinfection*</td>
<td>30 (2.4%)</td>
<td>7 (4.2%)</td>
<td>2 (3.1%)</td>
<td>3 (5.3%)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>31 (2.5%)</td>
<td>3 (1.8%)</td>
<td>4 (6.3%)</td>
<td>2 (3.5%)</td>
</tr>
<tr>
<td>Systolic blood pressure, mmHg**</td>
<td>115.6 (14.9)</td>
<td>118.4 (17.0)</td>
<td>123.7 (21.6)</td>
<td>120.5 (18.8)</td>
</tr>
<tr>
<td>Diastolic blood pressure, mmHg***</td>
<td>74.4 (10.3)</td>
<td>77.2 (13.3)</td>
<td>80.7 (14.4)</td>
<td>78.8 (12.6)</td>
</tr>
<tr>
<td>Smoking, current or former</td>
<td>924/1260 (73.3%)</td>
<td>124/164 (75.6%)</td>
<td>45/64 (70.3%)</td>
<td>44/57 (77.2%)</td>
</tr>
<tr>
<td>eGFR &lt; 60mL/min−1/1.73m**</td>
<td>80/1244 (6.4%)</td>
<td>14/162 (8.6%)</td>
<td>12/62 (19.4%)</td>
<td>14/55 (25.5%)</td>
</tr>
<tr>
<td><strong>Hemoglobin, g/dL</strong>*</td>
<td>12.5 (1.3)</td>
<td>12.1 (1.7)</td>
<td>11.8 (1.4)</td>
<td>11.3 (1.6)</td>
</tr>
<tr>
<td>**Serum albumin, g/dL, ***</td>
<td>4.2 (0.4)</td>
<td>4.2 (0.4)</td>
<td>3.9 (0.6)</td>
<td>3.7 (0.5)</td>
</tr>
<tr>
<td><strong>All-cause death</strong>*</td>
<td>74 (5.9%)</td>
<td>31 (18.8%)</td>
<td>13 (20.3%)</td>
<td>17 (29.8%)</td>
</tr>
<tr>
<td>AIDS death***</td>
<td>52 (4.1%)</td>
<td>23 (13.9%)</td>
<td>11 (17.2%)</td>
<td>11 (19.3%)</td>
</tr>
<tr>
<td>New ADI***</td>
<td>156 (12.4%)</td>
<td>28 (17.0%)</td>
<td>15 (23.4%)</td>
<td>15 (26.3%)</td>
</tr>
</tbody>
</table>

χ² test for categorical variables and Kruskal–Wallis for continuous variables.

*P < 0.05

**P < 0.01

***P < 0.001

Hepatitis C coinfection, hepatitis C antibody positive and RNA positive or unknown; hepatitis B coinfection, hepatitis B surface antigen positive.

DISCUSSION

In this well-characterized cohort of HIV-infected women enrolled before the widespread introduction of HAART, we identified a graded relationship between the degree of albuminuria and the risk of mortality. Although overt proteinuria has been associated with adverse outcomes in previous studies,1,2 the prognostic significance of microalbuminuria has not been described in HIV-infected individuals. In the current analysis, the detection of proteinuria or microalbuminuria on a single urine specimen was associated with an increased risk of mortality, even after adjustment for markers of HIV disease severity. These data suggest that microalbuminuria testing may provide useful prognostic information in HIV-infected individuals.

Although this is the first study to investigate the prognostic significance of microalbuminuria in patients with HIV, a number of limitations must be acknowledged. First, this analysis included only women enrolled before the widespread use of HAART, and results may not be generalizable to men or HAART-treated individuals. Although more than 50% of participants had a CD4 >350 cells per cubic millimeter at the index visit, the majority of deaths occurred in women with lower CD4. The relationship between albuminuria and all-cause death was consistent when stratified at a CD4 of 350 cells per cubic millimeter, although we had limited power to detect differences in the strength of this relationship between CD4 strata (data not shown). Because more than 70% of deaths were attributed to AIDS, we had limited power to analyze the relationship between albuminuria and non-AIDS death. Second, a small number of participants initiated HAART before the end of the study period. In a previous WIHS analysis using the same study period, the percentage of person–time on HAART was very low, and HAART use had no significant influence on mortality.11 Results of the current analysis were similar when HAART use was included as a time-dependent variable. Finally, it is possible that misclassification occurred due to the use of angiotensin converting enzyme inhibitors and other agents known to reduce albuminuria, limited sensitivity of dipstick assays for protein or microalbumin, or decreased sensitivity of microalbuminuria...
testing in banked urine specimens. This potential misclassification would be expected to bias our results toward the null.

The current study suggests that microalbuminuria testing may identify HIV-infected patients at increased risk for mortality. Although the mechanism of the observed association is not known, microalbuminuria has been hypothesized to reflect generalized endothelial dysfunction. In patients with HIV, microalbuminuria is associated with more advanced HIV disease and longer duration of infection. Consistent with these reports, the incremental risk of mortality associated with microalbuminuria was reduced, but not eliminated, after adjusting for markers of HIV disease severity. Nonetheless, microalbuminuria could serve as a noninvasive and accessible prognostic marker, particularly in resource-limited settings, where extensive laboratory testing is not feasible. Future studies should investigate whether microalbuminuria is associated with mortality in other HIV-infected populations and whether microalbuminuria testing is a cost-effective approach to identify patients who may benefit from earlier intervention.

**ACKNOWLEDGMENTS**

Data in this article were collected by the WIHS Collaborative Study Group with centers (Principal Investigators) at New York City/Bronx Consortium (K.A.); Brooklyn, NY (Howard Minkoff); Washington DC Metropolitan Consortium

**FIGURE 1.** Kaplan–Meier estimates of time to all-cause death and time to AIDS death.
(M.A.Y.); The Connie Wofsy Study Consortium of Northern California (Ruth Greenblatt); Los Angeles County/Southern California Consortium (Alexandra Levine); Chicago Consortium (Mardge Cohen); Data Coordinating Center (Stephen Gange). We are grateful to Johanna Goderre and Henry Sacks for their assistance.

REFERENCES